Exploring the Therapeutic Potential of Cordyceps Mushroom on SARS-CoV-2 Using Virtual Screening against Mpro and In Vitro Validation of Cordycepin.

Metadata-grounded summary

Citation abstract

Pathogenic coronavirus, including COVID-19, threatens human health, and there have been strong demands for efficient therapeutics. Cordyceps militaris is a medicinal mushroom that has long been used for immune enhancement, anticancer, and antiviral effects. Therefore, the inhibitory potentials of constituents of C. militaris against COVID-19 were analyzed using various virtual screening analyses. Among ten constituents of C. militaris, cordycepin, the major component, and 3'-deoxyuridine and 2'- O -methyl-adenosine showed strong binding affinity to M pro, a potential target for COVID-19 therapeutics. Considering the structure-activity relationship, nucleosides having deoxyribose and methoxyribose moiety are important for the affinity to M pro. Cordycepin is also bound to M pro mutants, and the binding mechanisms between cordycepin and M pro were investigated further by MD simulation and MM/PBSA analysis. Principal component analysis also confirmed the conformational change of M pro by cordycepin, which inhibits the function of M pro. In vitro, the efficacy of cordycepin was measured using Vero cells infected with SARS-CoV-2, which showed excellent inhibition with an IC 50 value of 29 μM. Conclusively, the constituents of C. militaris are expected to inhibit SARS-CoV-2 replication through binding to M pro. Therefore, C. militaris can be an essential therapeutic for coronavirus through the synergistic effect of its constituents.